Výsledky vyhledávání - "Jacques Näsström"

Akademický článek

Reply to a Comment Paper on the Published Paper by Canta, A. et al: 'Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity'—Antioxidants 2020, 9, 594

Autor: Annalisa Canta, Alessia Chiorazzi, Eleonora Pozzi, Giulia Fumagalli, Laura Monza, Cristina Meregalli, Valentina A. Carozzi, Virginia Rodriguez-Menendez, Norberto Oggioni, Jacques Näsström, Paola Marmiroli, Guido Cavaletti

Publikováno v: Antioxidants, Vol 9, Iss 9, p 807 (2020)

The comments sent by Stehr, Lundstom and Karlsson with reference to our article “Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fiber loss in a mouse model of oxaliplatin-induced peripheral neurotoxicity“ are very i

Externí odkaz: https://doaj.org/article/eca15d8e341f4f5cb716aaa1e791d1bb

Zobrazit plný text záznamu

Akademický článek

Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity

Publikováno v: Antioxidants, Vol 9, Iss 7, p 594 (2020)

Oxaliplatin (OHP) is an antineoplastic compound able to induce peripheral neurotoxicity. Oxidative stress has been suggested to be a key factor in the development of OHP-related peripheral neurotoxicity. Mangafodipir, a contrast agent possessing mito

Externí odkaz: https://doaj.org/article/6ea08a32b15b46a1ba40a13deca1175c

Zobrazit plný text záznamu

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)

Autor: Per Pfeiffer, Maryam Lustberg, Jacques Näsström, Stefan Carlsson, Anders Persson, Fumiko Nagahama, Guido Cavaletti, Bengt Glimelius, Kei Muro

Publikováno v: JNCI cancer spectrum. 6(6)

Background Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5013e9c43c7e526d1615b47f3737f0f
https://pubmed.ncbi.nlm.nih.gov/36308449

Zobrazit plný text záznamu

Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity

Autor: Laura Monza, Jacques Näsström, Eleonora Pozzi, Paola Marmiroli, Guido Cavaletti, Norberto Oggioni, G Fumagalli, Annalisa Canta, Alessia Chiorazzi, Virginia Rodriguez-Menendez, Cristina Meregalli, Valentina Alda Carozzi

Publikováno v: Antioxidants
Volume 9
Issue 7
Antioxidants, Vol 9, Iss 594, p 594 (2020)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::678596e247311f915e0e680886da6711

Zobrazit plný text záznamu

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx

Autor: Bengt, Glimelius, Nebojsa, Manojlovic, Per, Pfeiffer, Baadur, Mosidze, Galina, Kurteva, Mia, Karlberg, Devalingam, Mahalingam, Peter, Buhl Jensen, Jan, Kowalski, Marie, Bengtson, Malin, Nittve, Jacques, Näsström

Publikováno v: Acta oncologica (Stockholm, Sweden). 57(3)

Oxaliplatin causes disabling acute and chronic peripheral neuropathy. We explored the preventive effects of calmangafodipir, mimicking the mitochondrial enzyme manganese superoxide dismutase, thereby protecting cells from oxidative stress, in a place

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9ea1ccc1cbeb971fb7bca1b7e327e5be
https://pubmed.ncbi.nlm.nih.gov/29243552

Zobrazit plný text záznamu

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT)

Autor: Galina Kurteva, Peter Buhl Jensen, Mia Karlberg, Per Pfeiffer, Bengt Glimelius, Marie Helene Bengtson, Devalingam Mahalingam, Nebojsa Manojlovic, Malin Nittve, Jacques Näsström, Jan Kowalski, Baadur Mosidze

Publikováno v: Glimelius, B, Manojlovic, N, Pfeiffer, P, Mosidze, B, Kurteva, G, Karlberg, M, Mahalingam, D, Buhl Jensen, P, Kowalski, J, Bengtson, M, Nittve, M & Näsström, J 2018, ' Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)) : a placebo-controlled randomised phase II study (PLIANT) ', Acta Oncologica, vol. 57, no. 3, pp. 393-402 . https://doi.org/10.1080/0284186X.2017.1398836

PURPOSE: Oxaliplatin causes disabling acute and chronic peripheral neuropathy. We explored the preventive effects of calmangafodipir, mimicking the mitochondrial enzyme manganese superoxide dismutase, thereby protecting cells from oxidative stress, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde1826f4cf04ab2673909a061f14443

Zobrazit plný text záznamu

Intra-articular Duration of Durolane™ after Single Injection into the Rabbit Knee

Autor: Roland Hjelm, Åsa Wiebensjö, Katarina Edsman, Helena Lärkner, A. Urban Höglund, Anne Helander Kenne, Jacques Näsström, Lars I. Nord, Anders Karlsson

Publikováno v: Cartilage

Objective: The aim of the present study was to investigate the intra-articular duration of Durolane™ in a rabbit model to allow comparison between Durolane™ residence time and data reported for other hyaluronic acid products as well as native hya

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9237cd1a1f78796b86069d29ac76ce
https://doi.org/10.1177/1947603511400184

Zobrazit plný text záznamu

Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC)

Autor: Marie Helene Bengtson, Per Pfeiffer, Nebojsa Manojlovic, Bengt Glimelius, G. Kurteva, Devalingam Mahalingam, Jacques Näsström, Mia Karlberg, Baadur Mosidze

Publikováno v: Journal of Clinical Oncology. 34:10018-10018

10018Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major problem after oxaliplatin treatment. Calmangafodipir (CaM) has shown promising activities in model systems in preventin...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::414d69424b80f04e15f08ff9e4daa688
https://doi.org/10.1200/jco.2016.34.15_suppl.10018

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání